Astellas Pharma Inc. says it will buy U.S. pharmaceutical company Iveric Bio Inc., which focuses on ophthalmology treatments, for about $5.9 billion, as the Japanese drugmaker continues its merger and acquisition drive.
Astellas Pharma Inc. said Monday it will buy U.S. pharmaceutical company Iveric Bio Inc. for about $5.9 billion in its largest takeover, as the Japanese drugmaker pushes ahead with its acquisition. | May 1, 2023
Astellas Pharma to pay $40 per share for all outstanding shares of Iveric Bio, which specializes in ophthalmology, with transaction expected to close at end-Sept - Anadolu Ajansı
The Illinois federal court decision, Astellas US Holdings, Inc. v. Starr Indemnity & Liability Co.,which focuses on whether $50 million of Astellas’s settlement payment to the DOJ was covered Loss under the D&O policy